Peptide Gonadorelin OXY-GND (5mg) OxyPharma

Catalogue entry: Peptide Gonadorelin OXY-GND (5mg) OxyPharma. Labelled content: 5 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

Gonadorelin is the synthetic form of gonadotropin-releasing hormone, or GnRH. It acts on the pituitary reproductive-hormone axis governing LH and FSH, not on the GH-secretagogue pathway. Similar abbreviations should not obscure the difference from GHRP-2 or CJC-1295 DAC.

What the research measured

Spratt and colleagues studied GnRH in men with hypogonadotropic hypogonadism in the Annals of Internal Medicine in 1986. Quaas and colleagues reported a clinical cohort involving functional hypothalamic amenorrhoea in 2022. These are specific endocrine conditions. Results depend on the underlying diagnosis, pituitary function and clinical treatment context rather than the presence of a familiar peptide name alone.

Sporting claims and limitations

In sport, Gonadorelin is sometimes framed as a simple way to restore hormones after other substances. That claim cannot be established from reproductive-endocrinology studies. Signal timing and pattern affect the biological response, making it particularly misleading to infer an outcome from a label quantity. Fertility, sex-hormone balance and underlying endocrine disorders require their own clinical assessment.

Product identity and documentation

The catalogue records the selected labelled content and presentation without supplying a hormone-management protocol. Product documents should identify gonadorelin and its chemical form, the actual lot and relevant analytical methods. Authenticity, quality and formulation remain separate from molecular identity. A study in a defined endocrine disorder does not establish the suitability of an unrelated supplier vial for a healthy athlete.